



NEWS RELEASE

# Savara to Present at the 39th Annual Canaccord Genuity Global Growth Conference

2019-07-31

AUSTIN, Texas--(BUSINESS WIRE)--Jul. 31, 2019-- **Savara Inc.** (Nasdaq: SVRA), an orphan lung disease company, today announced that the Company's Chief Operating Officer, Taneli Jouhikainen, will present at the Canaccord Genuity Global Growth Conference on Wednesday, August 7, 2019 at 11:30 a.m. Eastern Time / 8:30 a.m. Pacific Time in the Montreal Room at the Intercontinental in Boston.

Interested parties can access a live audio webcast on the Investors page of the Savara website at [www.savarapharma.com/investors/events-presentations/](http://www.savarapharma.com/investors/events-presentations/). Please connect to the Company's website at least 15 minutes prior to the start of the presentation to ensure sufficient time for any software download that may be required for the webcast. An archived presentation will be available on Savara's website for 30 days.

## About Savara

Savara is an orphan lung disease company. Savara's pipeline comprises Molgradex, an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP), in Phase 2a development for nontuberculous mycobacterial (NTM) lung infection in both non-cystic fibrosis (CF) and CF-affected individuals with chronic NTM lung infection; and AeroVanc, a Phase 3-stage inhaled vancomycin for treatment of persistent methicillin-resistant *Staphylococcus aureus* (MRSA) lung infection in CF. Savara's strategy involves expanding its pipeline of potentially best-in-class products through indication expansion, strategic development partnerships and product acquisitions, with the goal of becoming a leading company in its field. The most recent acquisition is aerosolized amikacin/fosfomycin, a Phase 2-ready combination antibiotic for which the initial indication will focus on non-CF bronchiectasis patients with chronic lung infection and frequent exacerbations. Savara's management team has significant experience in orphan drug development and pulmonary medicine, identifying unmet needs, developing and acquiring new product candidates, and effectively

advancing them to approvals and commercialization. More information can be found at [www.savarapharma.com](http://www.savarapharma.com).  
(Twitter: @SavaraPharma, LinkedIn: [www.linkedin.com/company/savara-pharmaceuticals/](http://www.linkedin.com/company/savara-pharmaceuticals/))

View source version on businesswire.com: <https://www.businesswire.com/news/home/20190731005056/en/>

Source: Savara Inc.

Savara Inc. IR & PR

Anne Erickson ([anne.erickson@savarapharma.com](mailto:anne.erickson@savarapharma.com))

(512) 851-1366